Dishman Carbogen Amcis liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
1.36×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.23×1.23×1.14×0.75×1.07×
0.79×0.79×0.68×0.41×0.62×
804804367287309
525525276−627120
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DCAL₹136.00

Dishman Carbogen Amcis Limited

· Pharma & Health
₹ CrorePeersHIKALSOLARAPANACEABIOINDSWFTLABSAIPARENTINDOCOSMSPHARMAWINDLASMcap ₹2,132 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Altman Z-Score (Other Equity as RE)————1.36
Current Ratio1.070.751.141.231.23
Quick Ratio0.620.410.680.790.79
Cash, Equiv & ST Investments308.8287.4366.5803.9803.9
Working Capital120.0-626.5275.6525.1525.1
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.